Analytics-Driven AAV Development & Manufacturing

Ascend has invested in an industry-leading analytics platform with low-volume sample methods to preserve batch yields while ensuring AAV vector safety and potency.

Our comprehensive in-house analytics portfolio mitigates risks with robust data, including residual DNA testing for plasmid and host cell contamination, plus NGS and multiplex ddPCR for vector genome integrity.

Accurate full/empty capsid quantification is critical for dosing, potency, and reducing immunogenicity risks. We provide rapid, on-site analysis using mass photometry, orthogonal methods, and low-volume biophysical measurements like nanoDSF and subvisible particle assessment—ensuring precise, high-quality AAV production.